印度为防治致命的牛病,批准了世界首个LSD疫苗,该疫苗用于防治致命的牛病。 Biovet launches world's first LSD vaccine, approved in India, to combat deadly cattle disease.

Bharat生物技术的子公司Biovet获得印度药管局批准,使用其棉皮病(LSD)疫苗Biolumpivaxin,即Biolumpivaxin疫苗。 Biovet, a subsidiary of Bharat Biotech, received approval from India's drug regulator for its lumpy skin disease (LSD) vaccine, Biolumpivaxin. 这种疫苗是世界上第一种DIVA标志性疫苗,对感染和接种疫苗的动物加以区分。 This vaccine is the world's first DIVA marker vaccine, distinguishing between infected and vaccinated animals. 这一疾病已夺去大约20万头牛的性命,并影响到印度数以百万计的人。 The disease has killed around 200,000 cattle and affected millions more in India. 疫苗既安全又有效,每年可产生多达5亿剂量的疫苗,有助于疾病监测,减少对进口疫苗的依赖。 The vaccine, which is safe and effective, can produce up to 500 million doses annually, aiding in disease surveillance and reducing dependency on imported vaccines.